The ACAP1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the HeLa cell line, with targeted disruption of the ACAP1 gene. This polyclonal knockout product offers a heterogeneous loss-of-function model suitable for population-based studies, circumventing the limitations of clonal variation. It enables robust analysis of ACAP1-dependent phenotypes in a well-defined genetic background. Researchers can employ these cells to dissect mechanisms governing integrin-mediated adhesion and migration without the confounding effects of single-cell cloning.
HeLa cells are a human cervical epithelial cell line originating from an HPV18-positive cervical adenocarcinoma. Their extensive characterization, rapid proliferation, and amenability to genetic manipulation make them a standard platform for cancer cell biology. The transformed phenotype of HeLa cells, driven by HPV18 oncoproteins E6 and E7, provides a relevant milieu for studying ACAP1’s role in adhesion and motility pathways often hijacked during tumor progression. This host background allows investigation of ACAP1 in the context of high-risk HPV-associated oncogenesis.
ACAP1 functions as an ARF6-specific GTPase-activating protein (GAP) that critically regulates endocytic recycling of integrin ??1. It bridges cargo sorting at clathrin-coated pits with actin remodeling by interacting with clathrin heavy chain, the AP-2 adaptor complex, and Rab11a. Upstream activation occurs through integrin engagement and receptor tyrosine kinase signaling, mediated by ARF6-GEFs such as EFA6. Downstream, ACAP1 inactivation of ARF6 modulates Rab11a-dependent integrin trafficking and Rac1-mediated actin dynamics, governing cell adhesion and migration. The signaling hierarchy ARF6??ACAP1??Rab11/integrin ??1??Rac1/actin is central to cellular motility.
In HeLa cells, ACAP1 knockout disrupts a critical tumor-promoting axis. HPV18-positive cervical adenocarcinoma cells rely on dysregulated integrin recycling and actin remodeling for invasive behavior. Deletion of ACAP1 impairs the efficient trafficking of integrins to the leading edge, crippling cell motility and potentially reducing metastatic capacity. This model is valuable for dissecting how oncogenic signals hijack ARF6-mediated membrane trafficking to drive cancer cell dissemination. It also provides a platform for testing inhibitors of the ACAP1-ARF6 interface.
Research applications include cancer cell migration and invasion assays, endocytic trafficking studies, and integrin recycling visualization. Compatible techniques encompass Western blotting for ARF6-GTP levels, immunofluorescence microscopy of integrin ??1 recycling, transwell migration and Matrigel invasion assays, co-immunoprecipitation of ACAP1 with clathrin or AP-2, and live-cell imaging of endosomal dynamics. These functionalities position the ACAP1 knockout HeLa polyclonal cells as a versatile tool for studies in tumor biology and cytoskeletal regulation. For further details, contact Ascent Research.
